Hypertension, Portal clinical trials
The registry lists 376 studies for Hypertension, Portal across more than 10 countries. 115 are recruiting or about to start. 180 of them are mainly about Hypertension, Portal (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Esophageal and Gastric Varices too: 477 studies, 139 open.
Get an email when these change. Save the Hypertension, Portal studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Shanghai Zhongshan Hospital (15) · Northern Jiangsu People's Hospital (12) · West China Hospital (11) · Nanfang Hospital, Southern Medical University (11) · Hepatopancreatobiliary Surgery Institute of Gansu Province (10) · Taipei Veterans General Hospital, Taiwan (7) · Medical University of Vienna (7) · Shanghai Changzheng Hospital (6)
What is being tested here
Drugs under test in Hypertension, Portal studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Apixaban | 3 | 0 | 5 |
| Alverine | 3 | 3 | 4 |
| Carvedilol | 2 | 4 | 15 |
| Terlipressin | 2 | 0 | 5 |
| Somatostatin | 1 | 1 | 4 |
| Rifaximin | 1 | 2 | 4 |
| Vonoprazan | 1 | 1 | 2 |
| Mazdutide | 1 | 0 | 1 |
| Praziquantel | 1 | 1 | 1 |
| Contrast agent BR1 | 1 | 0 | 1 |
Drug classes tested here Factor Xa inhibitors 3 open · Beta blockers 2 open · Statins 9
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest
- Nov 2026EUS Guided Portal-systemic Pressure Gradient Measurement · Chinese University of Hong Kong
- Nov 2026Percutaneous Portal Vein Recanalization for Refractory Portal Hypertension in Children With Non-Cirrhotic Extrahepatic Portal Vein Obstruction · Papa Giovanni XXIII Hospital
- Dec 2026Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of Oesophageal Varices Trial. · King's College Hospital NHS Trust
- Dec 2026Preemptive TIPS for Gastric Variceal Bleeding in Patients With Cirrhosis · West China Hospital
- Dec 2026Preemptive TIPS for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis · West China Hospital
- Dec 2026EUS-guided Portal Pressure Gradient (PPG) Measurement: a Potential Alternative to the Traditional HVPG · Fundacio Privada Mon Clinic Barcelona
- Dec 2026EUS-guided Response Assessment to NSBB · Universitaire Ziekenhuizen KU Leuven
- Dec 2026Non-Invasive Portal and Hepatic Vein Pressure Estimation · Leiden University Medical Center
- Dec 2026The Feasibility, Safety, and Efficacy of EUS-Guided PSE: A Cohort Study · Qilu Hospital of Shandong University
- Dec 2026Clinical Study on the Selection of Endoscopic Varicose Disconnection Strategy Based on Natural Portal Shunt with Portal Hypertension · Zhejiang University
Who these studies take
Of the 69 Hypertension, Portal studies recruiting now, 33 (48%) set no upper age limit and 13 (19%) stop at 75 or younger. 1 (1%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (4%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 67 (97%) | 67 (97%) |
| 30 | 69 (100%) | 69 (100%) |
| 40 | 69 (100%) | 69 (100%) |
| 50 | 69 (100%) | 69 (100%) |
| 65 | 69 (100%) | 69 (100%) |
| 75 | 65 (94%) | 65 (94%) |
| 85 | 46 (67%) | 46 (67%) |
Across all 376 studies, recruiting or not: 38% stop at 75 or younger and 7% at 65; 10% take children; 0% are for women only and <1% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Hypertension, Portal studies take
Of 65 observational studies under Hypertension, Portal, half reached primary completion within 42 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Interventional, no phase | 41 mo19–72 · 61 studies | — | 41 mo15–72 · 57 studies |
| Observational | 42 mo30–256 · 65 studies | — | 43 mo31–256 · 61 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 14, 2026.
Newly registered7
- Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)Nov 12, 2026NCT07933328
- Treatment Outcomes and Predictors After Endovascular Intervention for Portal Hypertension-Related Gastrointestinal Bleeding in CirrhosisNov 5, 2026NCT07918378
- "Anticipant"-TIPS After a First Portal-hypertension-related Complication in CirrhosisOct 22, 2026NCT07889726
- Risk Stratification for Adverse Events in End-Stage Liver DiseaseOct 19, 2026NCT07880678
- Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLDOct 16, 2026NCT07877272
Show 2 moreShow fewer
Studies
Recruiting first, then most recently updated. Showing 50 of 376. Browse all 376 → or search them.
- Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)Not yet recruitingNCT07933328Phase 2
- VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)RecruitingNCT073903442 countries
- Natural History of Noncirrhotic Portal HypertensionRecruitingNCT024177401 country
- Treatment Outcomes and Predictors After Endovascular Intervention for Portal Hypertension-Related Gastrointestinal Bleeding in CirrhosisRecruitingNCT079183781 country
- Within-Session Repeatability of EUS-Guided Portal Pressure Gradient MeasurementNot yet recruitingNCT078772984 countries
- Non-selective Beta-blocker in Compensated Advanced Chronic Liver DiseaseRecruitingNCT06449339Phase 41 country
- "Anticipant"-TIPS After a First Portal-hypertension-related Complication in CirrhosisNot yet recruitingNCT07889726Not applicable1 country
- Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLDRecruitingNCT078772721 country
- Risk Stratification for Adverse Events in End-Stage Liver DiseaseNot yet recruitingNCT07880678
- Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver CirrhosisRecruitingNCT062652721 country
- 4D-Flow MRI Assessment of Portal Hypertension and TIPS Outcomes in CirrhosisRecruitingNCT07554183Not applicable1 country
- Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; RenewalRecruitingNCT05470205Phase 32 countries
- Baveno VIII Criteria for Portal Hypertension in Egyptian PatientsNot yet recruitingNCT07842666
- Noninvasive Prediction of Portal Hypertension in Cirrhosis Using Sound Touch ViscoelastographyRecruitingNCT063168691 country
- Effect of Handgrip Strength on Portal Vein Hemodynamics in Patients With Liver CirrhosisRecruitingNCT07116096Not applicable1 country
- EUS-guided Portal Pressure Gradient (PPG) Measurement: a Potential Alternative to the Traditional HVPGRecruitingNCT06863012Not applicable1 country
- Coil-Assisted Small-Diameter Covered-Stent Shunt Reduction for Refractory Hepatic Encephalopathy After TIPSRecruitingNCT07799948Not applicable1 country
- Body-weight Reduction Effect on Portal Hypertension in Compensated CirrhosisNot yet recruitingNCT07797101Not applicable
- hepatomiR cACLD StudyRecruitingNCT064325821 country
- Ultrasound With Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal HypertensionRecruitingNCT06797193Not applicable1 country
- Different Treatment Frequencies for Hepatic Fibrosis Due to SchistosomiasisNot yet recruitingNCT07754617Phase 2/31 country
- Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated CirrhosisNot yet recruitingNCT07755059Not applicable1 country
- Affect of Melatonin on Sleep and Cognition in CirrhosisRecruitingNCT07046429Not applicable1 country
- Cyanoacrylate Glue Versus Absorbable Gelatin Sponge for Gastric VaricesNot yet recruitingNCT07699354Not applicable1 country
- Cera™ Vascular Plug System Post-Market Clinical Follow-UpRecruitingNCT060990153 countries
- EUS-guided Response Assessment to NSBBRecruitingNCT06513195Not applicable1 country
- Austrian PBC RegistryRecruitingNCT075986691 country
- Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)Not yet recruitingNCT07585786
- Effect of Laparoscopic Splenectomy on Renal Function in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)Not yet recruitingNCT075857731 country
- Microplastics, Cirrhosis and Portal HypertensionRecruitingNCT072803901 country
- Effect of Laparoscopic Splenectomy on Lipid Profiles in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)Not yet recruitingNCT075883731 country
- Underdilated VCX-TIPS Versus EVL Plus NSBB for Secondary Prophylaxis of Variceal Bleeding in CirrhosisNot yet recruitingNCT07587671Not applicable1 country
- Treatment Outcomes for Portal Hypertension Esophageal and Gastric VaricesRecruitingNCT073586631 country
- Effect of LSD on Lipid Profiles in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)Not yet recruitingNCT075883341 country
- Ultrasound Prediction of Esophageal Variceal Bleeding RiskNot yet recruitingNCT07571876
- Freiburg TIPS RegistryRecruitingNCT057825561 country
- Early TIPS in Patients With Liver Cirrhosis and AscitesRecruitingNCT06576934Not applicable1 country
- Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver TransplantationRecruitingNCT07304466Not applicable1 country
- Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt PlacementRecruitingNCT074399391 country
- Apixaban-PK Trial: Preventing Portal Hypertension Complications in CirrhosisRecruitingNCT07521332Phase 41 country
- Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal DisconnectionRecruitingNCT07462091Not applicable1 country
- Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LSRecruitingNCT07461545Not applicable1 country
- Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSDRecruitingNCT07461532Not applicable1 country
- Optimizing Endoscopic and Interventional Treatment for Portal Hypertensive BleedingNot yet recruitingNCT07502729
- Multiparametric Ultrasound for the Noninvasive Diagnosis of Porto-sinusoidal Vascular Liver DisorderNot yet recruitingNCT07492862Not applicable1 country
- Non-invasive Predictors of Esophageal Varices and Their Correlation to Upper Endoscopic FindingsNot yet recruitingNCT07464522
- EUS Guided Portal-systemic Pressure Gradient MeasurementRecruitingNCT04633356Phase 1/21 country
- Portosystemic Shunt-associated Pulmonary Hypertension Multi-center Prospective Cohort StudyNot yet recruitingNCT07481877
- Indicators Affecting PVT RecanalizationRecruitingNCT074733751 country
- Fiber-Optic Navigation During TIPS Creation: A Prospective Pilot StudyNot yet recruitingNCT07470515Not applicable1 country